We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
days to go: Expired investment: £1,493,593
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their helath where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go: Expired investment: £737,480
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
days to go: Expired investment: £251,600
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go: Expired investment: £1,310,090
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings. 
days to go: Expired investment: £1,126,464
Metrion Biosciences is a pharmaceutical research organisation that provide a high quality drug discovery services for ion channel targets to clients on a fee-for-service or collaboration basis.
days to go: Expired investment: £465,150
Providing dental professionals with an online Personal Development Plan for their Continuing Professional Development. Dentinal Tubules currently has more than 2,100 individuals registered to use the service and over 2,700 dental practice professionals that are paying for a subscription. Dentinal Tubules hosts more than 1,500 educational and certified videos to help with a professional's CPD, in addition they also offer live courses, a livestream and an annual congress. Investments will be used to enhance, develop and bring the technology in-house.
days to go: Expired investment: £155,820
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
days to go: Expired investment: £5,634
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph